240 related articles for article (PubMed ID: 23990894)
1. Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Ben-Aharon I; Vidal L; Rizel S; Yerushalmi R; Shpilberg O; Sulkes A; Stemmer SM
PLoS One; 2013; 8(8):e70044. PubMed ID: 23990894
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2015 Jun; 151(2):251-9. PubMed ID: 25917869
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Nahleh Z; Abrams J; Bhargaval A; Nirmal K; Graff JJ
Clin Breast Cancer; 2010 Dec; 10(6):459-64. PubMed ID: 21147689
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
11. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Bonilla L; Ben-Aharon I; Vidal L; Gafter-Gvili A; Leibovici L; Stemmer SM
J Natl Cancer Inst; 2010 Dec; 102(24):1845-54. PubMed ID: 21098761
[TBL] [Abstract][Full Text] [Related]
12. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
[TBL] [Abstract][Full Text] [Related]
18. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F; Ceppi M; Lambertini M; Bruzzi P; Ugolini D; Bighin C; Levaggi A; Giraudi S; D'Alonzo A; Vaglica M; Blondeaux E; Sertoli MR; Pronzato P; Del Mastro L
Breast; 2017 Jun; 33():104-108. PubMed ID: 28360014
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
He M; Fan W; Zhang X
J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
